Loading clinical trials...

COMPLETEDNA

Combined Digital X-ray and Ultrasound Technique for Improved Detection and Characterization of Breast Lesions

NCT00721435•University of Michigan

Summary

The study will evaluate and refine a breast screening and diagnosis device.

Detailed Description

The device produces 3-D mammograms and ultrasound pictures of the breast at the same time and in the same position. This should help make sure that any area on a mammogram can be easily found in the ultrasound when using the new device. The 3-D mammograms should provide better visualization of the suspected lesion and improve diagnostic accuracy.

Eligibility

Age

25 - No limit years

Sex

FEMALE

Healthy Volunteers

Yes

Inclusion Criteria

•To participate in this research study you must be a female over the age of 25
•Have had a normal mammogram or are scheduled for a breast biopsy
•Have cysts or have been recommended to have a 6 month follow up mammogram after your biopsy.

Exclusion Criteria

•Male
•Under the age of 25
•Documented breast cancer

Locations (2)

University of Michigan

Ann Arbor, Michigan, United States

University of Michigan

Ann Arbor, Michigan, United States

Key Dates

Start Date

April 1, 2002

Primary Completion Date

December 1, 2014

Completion Date

October 1, 2016

Last Updated

January 24, 2017

Enrollment

183

ACTUAL participants

Conditions

Breast CancerMass CysticBenign Mass

Interventions

3D Tomosynthesis and ultrasound imaging

PROCEDURE

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

NCT04550494

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+29 more

View study

RECRUITINGPHASE1

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

NCT05673200

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 24, 2017Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Combined Digital X-ray and Ultrasound Technique for Improved Detection and Characterization of Breast Lesions

Inclusion Criteria

Exclusion Criteria

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

Safety and Feasibility of Robotic SP Nipple Sparing Mastectomy

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Breast Cancer